NETRF welcomes five new members to its Board of Scientific Advisors, a volunteer council of highly distinguished medical and research leaders who share NETRF’s commitment to advancing the diagnosis and treatment of neuroendocrine cancer.
Research to Advance Neuroendocrine Tumor Treatment The Neuroendocrine Tumor Research Foundation (NETRF) today announced $3.5 million in neuroendocrine tumor (NET) research grants to fund 12
A NETRF-funded clinical trial looks at a cancer vaccine called SurVaxM in neuroendocrine cancer to help slow or stop the spread of neuroendocrine tumors.
Highlights from NANETS 2019 symposium where leading NET experts presented progress and identified priorities for moving NET knowledge and care forward.
New grant explores precision drug delivery in NETs The American Association of Cancer Researchers (AACR) has awarded a NETRF-funded research grant to a Texas researcher
NETRF-funded researchers identified a cancer cell type that is associated with non-functional pancreatic neuroendocrine tumor (pNET) recurrence. Alpha-like pNET cell expression of the protein ARX can guide prognosis.
NETRF’s Board of Scientific Advisors and external reviewers will begin reading and ranking the 2019 requests for research funding. Wide Range of Requests for NET
Latest in NET Cancer Research Neuroendocrine Tumor Research Foundation (NETRF) held its 11th Annual Research Symposium on May 2-3, 2019, in Cambridge, MA. More than
NETRF & Broad Institute Work to Fill Research Void The lack of publicly available, reliable NET cell lines is a barrier in neuroendocrine tumor research,
Increasing Precision in Cancer Cell Death to Prevent Metastasis In housework and lawn work, it is important to have the right tool for the job.
